<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">465764975</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323111911.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170327e19900501xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00141255</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00141255</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Altered glycosylation in Madin-Darby canine kidney (MDCK) cells after transformation by murine sarcoma virus</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[E. Bruyneel, H. Hebray, M. De Mets, M. Mareel, J. Montreuil]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">The changes in glycosylation of an immortalized epithelial cell line (MDCK) before and after progression towards a more malignant phenotype have been studied. The parental MDCK-3 cells were immortalized after long-term passage in vitro and have shown no tendency for spontaneous acquisition of malignancy-related phenotypes such as tumorigenicity, invasion and metastasis. They conserved morphological and functional characteristics of the epithelial tissue of origin. The ras-MDCK cells acquired the fully malignant phenotype after transformation with a Harvey murine sarcoma virus; they were immortalized, invasive in vitro and produced invasive and also metastatic tumors after subcutaneous injection into nude mice. Using immobilized lectins and gel chromatography, before and after liberation of O-linked glycans from the peptide moieties and also after removal of terminal sialic acid, we have found differences in the glycosylpeptides of both whole cells and cell surface trypsinates from ras-MDCK cultures as compared to the parental MDCK-3 cultures: (i) more sialic acid in the N-linked tri- and tetra-antennary structures; (ii) more fucosylation in the N-glycosylpeptides; (iii) more bi-antennary N-glycosylpeptides and less O-linked glycans; and (iv) a lower molecular weight of the O-linked glycans probably due to a decreased sialylation. It is concluded that alterations in sialylation and fucosylation of the cell surface exposed glycans accompanied progression of MDCK-3 cells towards a more malignant phenotype.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Taylor &amp; Francis Ltd., 1990</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Bruyneel</subfield>
   <subfield code="D">E.</subfield>
   <subfield code="u">Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Hebray</subfield>
   <subfield code="D">H.</subfield>
   <subfield code="u">Unite Mixte de Recherche du CNRS no. 111, Laboratoire de Chimie Biologique de l'Université des Sciences et Techniques de Lille Flandres-Artois, F-59655, Villeneuve d'Ascq Cédex, France</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">De Mets</subfield>
   <subfield code="D">M.</subfield>
   <subfield code="u">Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Mareel</subfield>
   <subfield code="D">M.</subfield>
   <subfield code="u">Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Montreuil</subfield>
   <subfield code="D">J.</subfield>
   <subfield code="u">Unite Mixte de Recherche du CNRS no. 111, Laboratoire de Chimie Biologique de l'Université des Sciences et Techniques de Lille Flandres-Artois, F-59655, Villeneuve d'Ascq Cédex, France</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Clinical &amp; Experimental Metastasis</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">8/3(1990-05-01), 241-253</subfield>
   <subfield code="x">0262-0898</subfield>
   <subfield code="q">8:3&lt;241</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">8</subfield>
   <subfield code="o">10585</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00141255</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00141255</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Bruyneel</subfield>
   <subfield code="D">E.</subfield>
   <subfield code="u">Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Hebray</subfield>
   <subfield code="D">H.</subfield>
   <subfield code="u">Unite Mixte de Recherche du CNRS no. 111, Laboratoire de Chimie Biologique de l'Université des Sciences et Techniques de Lille Flandres-Artois, F-59655, Villeneuve d'Ascq Cédex, France</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">De Mets</subfield>
   <subfield code="D">M.</subfield>
   <subfield code="u">Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Mareel</subfield>
   <subfield code="D">M.</subfield>
   <subfield code="u">Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Montreuil</subfield>
   <subfield code="D">J.</subfield>
   <subfield code="u">Unite Mixte de Recherche du CNRS no. 111, Laboratoire de Chimie Biologique de l'Université des Sciences et Techniques de Lille Flandres-Artois, F-59655, Villeneuve d'Ascq Cédex, France</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Clinical &amp; Experimental Metastasis</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">8/3(1990-05-01), 241-253</subfield>
   <subfield code="x">0262-0898</subfield>
   <subfield code="q">8:3&lt;241</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">8</subfield>
   <subfield code="o">10585</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
